Joaquín Fra Rodríguez

5PUBLICATIONS
25CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 07, 2026
Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.

|Oct 30, 2025
Correction to: TERT Amplification a Risk Stratification Marker in Papillary Thyroid Carcinoma, Significantly Correlated with Tumor Recurrence and Survival.

Sara Gil-Bernabé, Noa Feás-Rodríguez, Enrique Pérez-Riesgo

|Apr 24, 2025
TERT Amplification a Risk Stratification Marker in Papillary Thyroid Carcinoma, Significantly Correlated with Tumor Recurrence and Survival.

Sara Gil-Bernabé, Noa Feás-Rodríguez, Enrique Pérez-Riesgo

|Sep 09, 2023
Multi-omics Characterization of Response to PD-1 Inhibitors in Advanced Melanoma.

Lucía Trilla-Fuertes, Angelo Gámez-Pozo, Guillermo Prado-Vázquez

|Jan 08, 2023
Sorting Transcriptomics Immune Information from Tumor Molecular Features Allows Prediction of Response to Anti-PD1 Therapy in Patients with Advanced Melanoma.

Lucía Trilla-Fuertes, Angelo Gámez-Pozo, Guillermo Prado-Vázquez

Pageof 1

Frequent Collaborators

3 joint publications

Elisabeth Pérez-Ruiz

2 joint publications

Sara Gil-Bernabé

2 joint publications

Noa Feás-Rodríguez

2 joint publications

Pérez-Riesgo Enrique